Announcement • Jun 20

+ 1 more update

Petros Pharmaceuticals, Inc. Announces Principal Financial Officer Changes, Effective June 18, 2026

Petros Pharmaceuticals, Inc. reported that on June 18, 2026, Mitchell Arnold, who served as the Company's Principal Financial Officer, mutually agreed to the separation from such roles, effective as of June 18, 2026. On June 18, 2026, the board of directors of the Company appointed Robert Weinstein to the position of Financial Officer effective immediately. Mr. Weinstein (66) has extensive accounting and finance experience, spanning more than thirty years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer. Since October 2013, Mr. Weinstein has been the Chief Financial Officer of TAO Synergies Inc. (formerly Synaptogenix, Inc.), a publicly-traded biotechnology company. From September 2011 to September 2013, Mr. Weinstein was an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. From March 2010 to August 2011, Mr. Weinstein was the Chief Financial Officer of Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company. From August 2007 to February 2010, Mr. Weinstein served as Chief Financial Officer of Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold in March 2010 to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide. Mr. Weinstein serves as a member of the board of directors of XWELL, Inc. Mr. Weinstein also serves as a member of the board of directors of PharmaCyte Biotech, Inc. Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his B.S. in accounting from the State University of New York at Albany.

Petros Pharmaceuticals, Inc. Stock Price

PTPI Share Price Performance

PTPI Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Petros Pharmaceuticals, Inc. Key Details

About PTPI

Recent PTPI News & Updates

Petros Pharmaceuticals, Inc. Announces Principal Financial Officer Changes, Effective June 18, 2026

Petros Pharmaceuticals, Inc. announced delayed annual 10-K filing

Recent updates

Petros Pharmaceuticals, Inc. Competitors

Endonovo Therapeutics

Grapefruit USA

Silexion Therapeutics

GNCC Capital